Roche is relying on launches or pivotal data for up to nine new drugs in the next three years to offset competition posed by biosimilar versions of its older drugs.
As patents start expiring in 2017, Roche will look to combat lost revenue with pipeline drugs such as atezolizumab to treat bladder and lung cancer, ocrelizumab for multiple sclerosis and ACE-910 for hemophilia.
Daniel O'Day, CEO of Roche's Pharmaceuticals Division, told investors, "I am absolutely convinced that with the strength of the portfolio, the readouts that are coming in over the next 18 months, and the opportunity to potentially launch eight or nine medicines between now and the end of 2017, we will mitigate the risk of biosimilars."
Read the Reuters article